S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in

Evolus Stock Forecast, Price & News

+0.04 (+0.35 %)
(As of 02/25/2021 12:00 AM ET)
Today's Range
Now: $11.50
50-Day Range
MA: $6.97
52-Week Range
Now: $11.50
Volume1.21 million shs
Average Volume1.86 million shs
Market Capitalization$388.11 million
P/E RatioN/A
Dividend YieldN/A
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.
Evolus logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EOLS
Year FoundedN/A



Sales & Book Value

Annual Sales$34.92 million
Book Value$2.38 per share


Net Income$-90,030,000.00
Net Margins-120.63%


Market Cap$388.11 million
Next Earnings DateN/A


Overall MarketRank

1.33 out of 5 stars

Medical Sector

669th out of 1,957 stocks

Pharmaceutical Preparations Industry

334th out of 771 stocks

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
+0.04 (+0.35 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Evolus (NASDAQ:EOLS) Frequently Asked Questions

Is Evolus a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Evolus stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EOLS, but not buy additional shares or sell existing shares.
View analyst ratings for Evolus
or view top-rated stocks.

What stocks does MarketBeat like better than Evolus?

Wall Street analysts have given Evolus a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evolus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) released its quarterly earnings results on Thursday, October, 29th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.06. The company earned $17.66 million during the quarter, compared to the consensus estimate of $12.40 million. Evolus had a negative net margin of 120.63% and a negative trailing twelve-month return on equity of 121.11%.
View Evolus' earnings history

How has Evolus' stock price been impacted by Coronavirus (COVID-19)?

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EOLS stock has increased by 94.6% and is now trading at $11.50.
View which stocks have been most impacted by COVID-19

What guidance has Evolus issued on next quarter's earnings?

Evolus issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, February, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $56.5-56.5 million, compared to the consensus revenue estimate of $58.37 million.

What price target have analysts set for EOLS?

10 Wall Street analysts have issued twelve-month target prices for Evolus' stock. Their forecasts range from $5.00 to $25.00. On average, they anticipate Evolus' stock price to reach $13.00 in the next year. This suggests a possible upside of 13.0% from the stock's current price.
View analysts' price targets for Evolus
or view top-rated stocks among Wall Street analysts.

Who are Evolus' key executives?

Evolus' management team includes the following people:
  • Mr. David Moatazedi, Pres, CEO & Director (Age 43, Pay $1.11M)
  • Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 63, Pay $600.2k)
  • Dr. Rui Avelar Dip.SportMed, M.D., C.CFP, Chief Medical Officer and Head of R&D (Age 59, Pay $1.28M)
  • Mr. Alejandro Sabad, VP of Operations
  • Mr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury
  • Mr. Jeffrey J. Plumer, Gen. Counsel
  • Ms. Crystal Muilenburg, VP of Corp. Communications & PR
  • Mr. Kurt Knab, VP of Sales
  • Mr. Michael Mazen Jafar, Chief Commercial Officer (Age 40)

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Evolus' key competitors?

What other stocks do shareholders of Evolus own?

When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.39%), Northern Trust Corp (0.81%), Renaissance Technologies LLC (0.75%), Citigroup Inc. (0.33%), Squarepoint Ops LLC (0.29%) and Nuveen Asset Management LLC (0.25%). Company insiders that own Evolus stock include Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Rui Avelar, Simone Blank and Vikram Malik.
View institutional ownership trends for Evolus

Which major investors are selling Evolus stock?

EOLS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., LPL Financial LLC, Northern Trust Corp, Bank of New York Mellon Corp, and Nuveen Asset Management LLC.
View insider buying and selling activity for Evolus
or view top insider-selling stocks.

Which major investors are buying Evolus stock?

EOLS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Squarepoint Ops LLC, SG Americas Securities LLC, JPMorgan Chase & Co., CM Management LLC, Virtu Financial LLC, Citigroup Inc., and Hsbc Holdings PLC. Company insiders that have bought Evolus stock in the last two years include David N Gill, Kristine Romine, Simone Blank, and Vikram Malik.
View insider buying and selling activity for Evolus
or or view top insider-buying stocks.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $11.50.

How much money does Evolus make?

Evolus has a market capitalization of $388.11 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis.

How many employees does Evolus have?

Evolus employs 125 workers across the globe.

What is Evolus' official website?

The official website for Evolus is www.evolus.com.

Where are Evolus' headquarters?

Evolus is headquartered at 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]

This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.